Drug Trial Radar · NCT00971165
Diuretics and Angiotensin-Receptor Blocker Agents in Patients With Stage I Hypertension
Last checked: Nov 20, 2026Latest source record: Feb 12, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
655
Actual
Start
Jul 2010
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Hospital de Clinicas de Porto AlegreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Financiadora de Estudos e Projetos
- First posted
- Sep 3, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
High blood pressure is the major risk factor for Cardiovascular disease (CVD). The prevalence of hypertension in Brazil was established in population-based studies conducted in different cities and States, varying from 22.3 to 44% of adults. The benefit of drug treatment of hypertension to prevent major cardiovascular events was consistently demonstrated in a large series of clinical trials controlled by placebo. Diuretics are at least as efficacious as other blood pressure-lowering drugs, are well tolerated, have longer duration of action and the advantage of very low cost to be used in a population intervention. Chlorthalidone is the more efficacious agent. Its main limitation is to induce hypokalemia in a proportion of patients, an adverse effect that can be antagonized by a potassium-sparing diuretic, as amiloride. A study comparing diuretic with an ARB agent is therefore recommendable in Brazil, in order to support the decisions of the Health Secretary in regard to blood pressure agents supply for the Brazilian population. Such a study was demanded and funded by the Health and Technology Ministries in Brazil.
Conditions
- Hypertension
- Cardiovascular Disease
Interventions
losartanDrug
Oral losartan up to 100 mg daily fo 18 months
Chlorthalidone plus amilorideDrug
Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood pressure variation and proportion of use of add-on drugsTime frame: 18 months
- Adverse eventsTime frame: 18 months
- Development or worsening of microalbuminuria and of left ventricular hypertrophy in the EKG.Time frame: 18 monyhs
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Hospital de Clínicas de Porto Alegre, UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clínicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.